Clinical trial
V710 First-In-Man (FIM) Study (V710-001)
NCT00303069 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00303069 |
|---|---|
| Title | V710 First-In-Man (FIM) Study (V710-001) |
| Official title | A Sequential-Panel, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Single Dose of Merck 0657nI Staphylococcus Aureus Vaccine in Healthy Adults 18 to 55 Years of Age |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Staphylococcal Infections |
| Intervention type | Biological |
| Interventions | V710, Comparator: Placebo |
| Enrollment | 124 |
| Start date | Nov 1, 2005 |
| Primary completion | Jul 1, 2006 |
| Completion | Jul 1, 2006 |
| First posted | Mar 15, 2006 |
| Last update posted | Jul 22, 2015 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: